Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥51 | ¥47 | ¥45 | ¥43 |
| % Growth | 8% | 4% | 3.8% | – |
| Cost of Goods Sold | ¥42 | ¥37 | ¥35 | ¥32 |
| Gross Profit | ¥9 | ¥10 | ¥10 | ¥11 |
| % Margin | 17.1% | 21% | 22.9% | 26.4% |
| R&D Expenses | ¥0 | ¥2 | ¥2 | ¥2 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥6 | ¥3 | ¥3 | ¥3 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥6 | ¥6 | ¥5 | ¥5 |
| Operating Income | ¥3 | ¥4 | ¥5 | ¥7 |
| % Margin | 5.2% | 8.3% | 11.5% | 15.1% |
| Other Income/Exp. Net | ¥0 | ¥0 | -¥0 | ¥0 |
| Pre-Tax Income | ¥3 | ¥4 | ¥5 | ¥7 |
| Tax Expense | ¥1 | ¥1 | ¥2 | ¥2 |
| Net Income | ¥2 | ¥3 | ¥4 | ¥5 |
| % Margin | 3.8% | 7% | 8% | 10.7% |
| EPS | 62.72 | 105 | 113.82 | 152.45 |
| % Growth | -40.3% | -7.7% | -25.3% | – |
| EPS Diluted | 62.72 | 105 | 113.71 | 152.45 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥0 | ¥0 | ¥0 | ¥0 |
| Depreciation & Amortization | ¥4 | ¥4 | ¥4 | ¥3 |
| EBITDA | ¥7 | ¥8 | ¥9 | ¥10 |
| % Margin | 14.6% | 16.9% | 19.9% | 22.7% |